Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 5 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 5 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W O ELECTROLYTES.
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER vs TRAVASOL 5.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy via glycolysis and oxidative phosphorylation.
TRAVASOL 5.5% W/O ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and nitrogen balance in patients unable to tolerate enteral nutrition. It serves as a substrate for gluconeogenesis and other metabolic processes.
Intravenous infusion: 1-1.5 g amino acids/kg/day (equivalent to 28-43 mL/kg/day of Aminosyn II 3.5% in D5W). Rate: infuse via central line at ≤100 mL/hour; peripheral line at ≤125 mL/hour. Adjust based on nitrogen balance and metabolic response.
Intravenous infusion, 500 mL to 2000 mL per day as a component of total parenteral nutrition (TPN), providing 5.5% amino acids. Rate should be individualized based on metabolic requirements and tolerance.
None Documented
None Documented
Not applicable as a mixture; individual components have varying half-lives. Dextrose: rapid distribution, half-life <1 hour. Amino acids: half-life of infused amino acids is short (minutes) due to metabolism.
Not applicable as a fixed drug; the clearance of infused amino acids follows saturable kinetics with a functional half-life of approximately 30-60 minutes for free amino acids in plasma, reflecting rapid uptake and metabolism. Clinical context: continuous infusion maintains steady-state levels.
Aminosyn II 3.5% in Dextrose 5% contains amino acids and dextrose. Amino acids are metabolized; negligible renal excretion of intact amino acids. Dextrose is metabolized. No biliary/fecal elimination of intact drug.
Primarily renal excretion of amino acids and metabolites; approximately 70-80% of infused amino acids are converted to urea and excreted in urine, with the remainder undergoing metabolism or incorporation into body proteins. Biliary/fecal excretion is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution